FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency's five criteria for determining "sameness" of generic enoxaparin to Sanofi-Aventis's low molecular weight heparin could serve as guideposts for future biosimilar approvals.
You may also be interested in...
Enoxaparin Generic Saga Continues: Momenta's Manufacturing Patent Invalid
Jury verdict comes seven years after Momenta/Sandoz launched generic version of Lovenox; firms sought treble damages from Amphastar for willful infringement of manufacturing process patent.
Enoxaparin Generic Saga Continues: Momenta's Manufacturing Patent Invalid
Jury verdict comes seven years after Momenta/Sandoz launched generic version of Lovenox; firms sought treble damages from Amphastar for willful infringement of manufacturing process patent.
Insider Trading By Ex-FDA Official Puts Spotlight On Agency Practices
After Office of Generic Drugs Deputy Director Gordon Johnston left FDA, he joined GPhA and 'tricked' a former colleague into sharing info on generic Lovenox on behalf of a hedge fund he was secretly working for, SEC says.